The FDA has issued Medtronic clearance to market the InterStim sacral nerve stimulation therapy system for people with chronic fecal incontinence. The pacemaker-like device has already been FDA ...
announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...
DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
Certain healthcare conditions often go unspoken, leading to silent struggles that affect the lives of many. Overactive bladder (OAB) and fecal incontinence (FI) are two such conditions, impacting ...
Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...
Medtronic plc today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio’s recharge-free device – and it ...
Medtronic has received FDA approval for a new implant aimed at improving bladder control, with a small device placed near the ...
CHICAGO, March 9 (Reuters) - Medtronic Inc said on Wednesday it resolved two warning letters issued by U.S. health regulators in 2009, clearing the way for new product approvals. Sign up here. With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback